SOURCE: BioCentury Publications, Inc.

September 04, 2012 09:00 ET

BioCentury and Thomson Reuters to Convene the 19th Annual NewsMakers in the Biotech Industry in New York

Conference to Feature 40 Companies With Tier-Jumping Potential for 2013, Plus a Special Clinician Roundtable on New Obesity Drugs

REDWOOD CITY, CA and NEW YORK, NY--(Marketwire - Sep 4, 2012) - BioCentury and Thomson Reuters will convene the 19th Annual NewsMakers in the Biotech Industry in New York City this Friday, September 7th at 8 a.m. at the Millennium Broadway Hotel & Conference Center.

The event showcases 40 biopharma companies independently selected on the basis of key clinical, regulatory and commercial milestones that will drive valuations going into 2013. New for this year's event is a panel discussion on how physicians and patients are expected to adopt the new obesity pharmacopeia. More than 600 life science investment professionals and pharmaceutical business development and licensing executives have pre-registered for the event. Pre-registration is available through the Thomson Reuters web site at

Money managers attending NewsMakers control nearly half a trillion dollars in equity assets, including more than $50 billion already committed healthcare assets and $14 billion in biotech assets.

The 2012 NewsMakers Presenting Companies

The 40 presenting companies represent an independently selected mix of companies with near-term commercial, regulatory and clinical milestones. The presenting companies were screened using BioCentury's industry analysis and proprietary databases, including the BCIQ online business intelligence platform.

The 2012 Class of NewsMakers presenting companies are outpacing the biotech market. Collectively, the Class of 2012 has raised $3.8 billion in capital since the beginning of 2011, including $2.6 billion this year. The aggregate market cap of the NewsMakers companies increased from $15.2 billion to $24 billion in 2012. This is a 58% increase, compared with a 26% jump in the BioCentury 100 Index and a 30% gain in the NASDAQ Biotechnology Index (NBI).

The NewsMakers also have 30 marketed products, seven newly approved compounds and eight compounds under regulatory review, including two with near-term PDUFA dates. The group is conducting more than 250 clinical trials, including 36 Phase III trials and more than 120 Phase II trials across cancer, metabolic, neurology, gastrointestinal and cardiovascular indications.

Agenus Inc. (AGEN)
Alnylam Pharmaceuticals Inc. (ALNY)
Arena Pharmaceuticals Inc. (ARNA)
ArQule Inc. (ARQL)
Array BioPharma Inc. (ARRY)
Astex Pharmaceuticals Inc. (ASTX)
BioMarin Pharmaceutical Inc. (BMRN)
Cempra Inc. (CEMP)
ChemoCentryx Inc. (CCXI)
Coronado Biosciences Inc. (CNDO)
Curis Inc. (CRIS)
Durata Therapeutics Inc. (DRTX)
Exelixis Inc. (EXEL)
Galena Biopharma Inc. (GALE)
GTx Inc. (GTXI)
Horizon Pharma Inc. (HZNP)
Hyperion Therapeutics Inc. (HPTX)
ImmunoCellular Therapeutics Ltd. (IMUC)
Infinity Pharmaceuticals Inc. (INFI)
The Medicines Co. (MDCO)
Medivation Inc. (MDVN)
Nektar Therapeutics (NKTR)
NeoStem Inc. (NBS)
Omeros Corp. (OMER)
Orexigen Therapeutics Inc. (OREX)
Orexo AB (ORX)
QRxPharma Ltd. (QRX; QRXPY)
Resverlogix Corp. (RVX)
SciClone Pharmaceuticals Inc. (SCLN)
Spectrum Pharmaceuticals Inc. (SPPI)
Sucampo Pharmaceuticals Inc. (SCMP)
Sunesis Pharmaceuticals Inc. (SNSS)
Tesaro Inc. (TSRO)
Threshold Pharmaceuticals Inc. (THLD)
Trius Therapeutics Inc. (TSRX)
Vanda Pharmaceuticals Inc. (VNDA)
Vical Inc. (VICL)
Vivus Inc. (VVUS)
Ziopharm Oncology Inc. (ZIOP)

See the Presenting Company schedule and additional program highlights at

Obesity Panel Discussion with Q&A

This year's NewsMakers conference features a special physician roundtable and Q&A discussion on the new obesity drugs that are poised to hit the market. The panelists are: Caroline M. Apovian, M.D., FACP, FACN, Associate Professor of Medicine and Pediatrics at Boston University School of Medicine and the Director of the Nutrition and Weight Management Center and the Clinical Research and Obesity Research Center at Boston Medical Center; and Louis J. Aronne, M.D., F.A.C.P., Clinical Professor of Medicine at Weill Cornell Medical College-New York Presbyterian Hospital.

"The key opinion leader discussion is a unique opportunity for investors and analysts to hear first-hand from physicians how these treatment breakthroughs will be prescribed to meet individual patient profiles," said David Flores, President and CEO of BioCentury. "This events-driven roundtable reflects the core focus of NewsMakers over the past two decades."

Sponsors Demonstrate Long-Term Commitment to Industry

Anchored by Gold Sponsor MLV & Co., the NewsMakers 2012 sponsors are leaders from both the public and private capital markets: Brinson Patrick; Ladenburg Thalmann; and WBB Securities.

Future BioCentury Conferences

NewsMakers is one of two premier investor conferences organized annually by BioCentury and Thomson Reuters. The next conference, Future Leaders in the Biotech Industry, will take place in New York City on April 5, 2013.

BioCentury is one of the organizers of the upcoming SciBX Summit on Innovation in Drug Discovery & Development to be held in Boston on September 21st in conjunction with EBD Group's BioPharm America™ meeting.

BioCentury is also an organizer of BioEquity Europe, an annual European biotech investor conference. BioEquity Europe 2013 will take place in Stockholm, Sweden, May 22 - 23, 2013.

About BioCentury

Now in its 20th year, BioCentury Publications, Inc. provides essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators and public policy makers, and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia.

BioCentury's titles include the flagship BioCentury®, the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange™ translational science partnership with Nature Publishing Group; and its BioCentury Extra™ online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence™, an online business intelligence resource. BioCentury also produces its BioCentury This Week biotech public affairs television program in partnership with the Gannett-owned WUSA9 CBS affiliate in Washington, D.C. The program is aired in Washington each Sunday as part of the WUSA9 Sunday Morning Power Block, on Public Broadcasting System member stations in selected markets and distributed globally online at

For more information, visit and

About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to